Basiliximab following penetrating risk-keratoplasty - A prospective randomized pilot study;Basiliximab als monotherapie nach perforierender risikokeratoplastik - Eine prospektive randomisierte pilotstudie

Klinische Monatsblatter fur Augenheilkunde

Volumn 225, Issue 1, 2008, Pages 62-65

  Birnbaum, Florian ^a   Jehle, T ^a   Schwartzkopff, J ^a   Sokolovska, Y ^b   Bohringer D ^a   Reis, A ^a   Reinhard, T ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Basiliximab; Immunosuppression; Penetrating keratoplasty

Indexed keywords

BASILIXIMAB; CYCLOSPORIN A; FLUOCORTOLONE; FLUOCORTOLONE CAPROATE; INFLANEFRAN FORTE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE ACETATE; SANDIMMUN OPTORAL; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNITY; KERATOPLASTY; MONOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ANTIBODIES, MONOCLONAL; CHEMOTHERAPY, ADJUVANT; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KERATOPLASTY, PENETRATING; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME;

EID: 39149125787     PISSN: 00232165     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1027129     Document Type: Article

References (22)

1. Alldredge OC, Krachmer JH. Clinical types of corneal transplant rejection. Their manifestations, frequency, preoperative correlates, and treatment. Arch Ophthalmol 1981; 99: 599-604
2. Bertelmann E, Reinhard T, Pleyer U. Current practice of immune prophylaxis and therapy in perforating keratoplasty. A survey of members of the Cornea Section of the German Ophthalmological Society. Ophthalmologe 2003; 100: 1031-1035
3. Birnbaum F, Böhringer D, Sokolovska Y et al. Immunosuppression with cyclosporine a and mycophenolate mofetil after penetrating high-risk keratoplasty: a retrospective study. Transplantation 2005; 79: 964-968
4. Birnbaum F, Maier P, Reinhard T. Intracameral application of corticosteroids for treating severe endothelial rejection after penetrating keratoplasty. Ophthalmologe 2007; 104: 813-816
5. Birnbaum F, Reis A, Böhringer D et al. An open prospective pilot study on the use of rapamycin after penetrating high-risk keratoplasty. Transplantation 2006; 81: 767-772
6. Birnbaum F, Reis A, Reinhard T. Immunosuppression following penetrating keratoplasty. Ophthalmologe 2007; 104: 371-372
7. Hill JC. Systemic cyclosporine in high-risk keratoplasty. Short- versus long-term therapy. Ophthalmology 1994; 101: 128-133
8. Hill JC. Immunosuppression in corneal transplantation. Eye 1995; 9 (Pt 2): 247-253
9. Hoffmann F. Suture technique for perforating keratoplasty (author's transl). Klin Monatsbl Augenheilkd 1976; 169: 584-590
10. Kahan BD, Rajagopalan PR, Hall M United States Simulect Renal Study Group. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2- receptor monoclonal antibody. Transplantation 1999; 67: 276-284
11. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481
12. Nashan B, Moore R, Amlot P CHIB 201 International Study Group.. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997; 350: 1193-1198
13. Pleyer U, Weidle EG, Lisch W et al. Clinical types of immunologic transplant reactions following perforating keratoplasty. Fortschr Ophthalmol 1990; 87: 14-19
14. Reinhard T, Böhringer D, Enczmann J et al. Improvement of graft prognosis in penetrating normal-risk keratoplasty by HLA class I and II matching. Eye 2004; 18: 269-277
15. Reinhard T, Hutmacher M, Sundmacher R. Acute and chronic immune reactions after penetrating keratoplasty with normal immune risk. Klin Monatsbl Augenheilkd 1997; 210: 139-143
16. Reinhard T, Mayweg S, Sokolovska Y et al. Systemic mycophenolate mofetil avoids immune reactions in penetrating high-risk keratoplasty: preliminary results of an ongoing prospectively randomized multicentre study. Transpl Int 2005; 18: 703-708
17. Reinhard T, Reis A, Böhringer D et al. Systemic mycophenolate mofetil in comparison with systemic cyclosporin A in high-risk keratoplasty patients: 3 years' results of a randomized prospective clinical trial. Graefes Arch Clin Exp Ophthalmol 2001; 239: 367-372
18. Reinhard T, Spelsberg H, Henke L et al. Long-term results of allogeneic penetrating limbo-keratoplasty in total limbal stem cell deficiency. Ophthalmology 2004; 111: 775-782
19. Reinhard T, Sundmacher R, Godehardt E et al. Preventive systemic cyclosporin A after keratoplasty at increased risk for immune reactions as the only elevated risk factor. Ophthalmologe 1997; 94: 496-500
20. Reinhard T, Sundmacher R, Heering P. Systemic ciclosporin A in high-risk keratoplasties. Graefes Arch Clin Exp Ophthalmol 1996; 234 (Suppl 1): S115-S121
21. Reis A, Birnbaum F, Reinhard T. Systemic immunosuppressives after penetrating keratoplasty. Ophthalmologe 2007; 104: 373-380
22. Schmitz K, Hitzer S, Behrens-Baumann W. Immune suppression by combination therapy with basiliximab and cyclosporin in high risk keratoplasty. A pilot study. Ophthalmologe 2002; 99: 38-45